-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A global trial led by researchers at University College London (UCL) showed that a once-a-day antiretroviral drug is low-cost, easy to take for children, and is more effective than standard treatments in suppressing HIV
The study, published in The New England Journal of Medicine, found that compared with standard therapies, dolutegravire-based treatment options have been widely used in adults, reducing the number of young adults aged 3-18 years.
These findings are based on a randomized controlled trial called ODYSSEY, which involved more than 700 children from 29 clinical centers in Africa, Europe and Asia.
This trial is sponsored by the Penta Foundation and funded by ViiV Healthcare.
Professor Diana Gibb (University College London MRC Clinical Trial Group) is the lead investigator of the Odyssey trial and one of the senior authors of this paper.
“Children’s medical care often lags far behind adults because of the need for separate formulations and research
The lead author of the study, Dr.
"Dolutravir is a small tablet that is usually taken once a day.
In this study, the researchers found that 14% of children treated with dolutagravir experienced treatment failure within two years, compared with 22% of children receiving standard treatment
Evidence from adults suggests that dolutegravir has a high genetic barrier to resistance, which means that over time, the virus is unlikely to develop resistance to it
Past studies have shown that dolutagravir may be related to weight gain in adults, but researchers said that the new research results are reliable for children, and children taking dolutagravir will gain more in two years.
In the main experiment, all children weighed more than 14 kg, and most of them were over 6 years old
Participants in the trial came from Uganda, Zimbabwe, South Africa, Thailand, the United Kingdom, Spain, Portugal and Germany
Early findings from the Odyssey trial showed that children weighing 20 kg or more can safely take adult doses of dolutgravir, which provides dosing guidance for the WHO and helps in the United States and Europe during 2020 Obtain a new license for the drug
Dr.
Dolutagravir is an integrase inhibitor—that is, it inhibits HIV by inhibiting integrase, which is an enzyme required for virus replication
.
